

VEGF-A/VEGF-B/VEGF-C expressions in non-hereditary, non-metastatic pheochromocytoma

Ichiro Abe^{1,2}, Farhadul Islam³, Chung Yau Lo⁴, Victor Liew⁵, Suja Pillai^{1,6} and Alfred K. Lam^{1,6}

¹School of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia, ²Department of Endocrinology and Diabetes Mellitus, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan, ³Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh, ⁴Department of Surgery, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, ⁵Department of Surgery, Gold Coast Private Hospital, Gold Coast, Queensland and ⁶School of Biomedical Sciences, Faculty of Medicine, University of Queensland, Brisbane, Australia

Summary. Vascular endothelial growth factor (VEGF) is important in pathogenesis of different cancers. The aim of this study is to investigate the relationships between different VEGFs and clinicopathological factors in patients with pheochromocytomas. Twenty patients (10 men; 10 women) with non-hereditary, non-metastatic pheochromocytomas were examined for *VEGF* mRNA expressions by polymerase chain reaction. The expressions were correlated with the clinical and pathological factors of the patients. In addition, mouse double minute 2 (MDM2) expression in these tumours were studied by immunohistochemistry. High expressions of *VEGF-A*, *VEGF-B*, and *VEGF-C* mRNA were detected in 11 (55%), 9 (45%), and 9 (45%) of the tumours respectively. High expression of *VEGF-A* in pheochromocytomas was significantly correlated with the tumour size ($p=0.025$) but did not correlate with patients' age, gender, and tumour laterality. Besides, there was a trend of *VEGF-A* expression correlated with MDM2 expression ($p=0.064$). On the other hand, expressions of *VEGF-B* and *VEGF-C* were not significantly correlated with tumour size, patients' age, gender, tumour laterality, and MDM2 expression. In addition, high expressions of *VEGF-B* and *VEGF-A* were associated with increase of tumour size ($p=0.042$). Co-expression of different *VEGFs* did not correlate with MDM2 expression. To conclude, there is a role for VEGF-A/VEGF-B/VEGF-C in the pathogenesis of non-hereditary, non-metastatic pheochromocytomas.

Key words: Pheochromocytoma, VEGF, Vascular endothelial growth factor, Mouse double minute 2, mdm2

Corresponding Author: Professor Alfred Lam, Head of Pathology, Griffith Medical School, Gold Coast Campus, Gold Coast QLD 4222, Australia. e-mail: a.lam@griffith.edu.au
 DOI: 10.14670/HH-18-329

Introduction

Pheochromocytoma is a neuroendocrine tumour derived from chromaffin cells in adrenal medulla (Lam, 2015). In the current classification of endocrine tumours by World Health Organisation (WHO), the term “metastatic pheochromocytoma” is used instead of “malignant pheochromocytoma” as pheochromocytoma could have metastatic potential and there is no unequivocal histological system to assess the biological aggressiveness of the tumour (Lam, 2017; Lloyd et al., 2017). Pheochromocytoma usually produces excess catecholamines with clinical symptoms related to hypertension and hyperglycaemia (Bravo, 1994; Abe et al., 2019; Tevosian and Ghayee, 2019). Eisenhofer and co-workers showed the amount of metanephrines released by the tumour were positively correlated with tumour size (Eisenhofer et al., 2005). Moreover, pheochromocytoma could lead to pheochromocytoma crisis, which is a life-threatening endocrine emergency with reported mortality as high as 85% (Newell, 1998; Abe et al., 2012). Riester and co-workers showed the development of pheochromocytoma crisis was significantly associated with increase of size of the tumour (Riester, et al, 2015). Considering these findings, management of pheochromocytoma, particularly for big pheochromocytomas, is very important.

Recent advances in genomic medicine reveal many new genetic mutations in pheochromocytoma (Papathomas et al., 2021). Approximately 40% of pheochromocytomas were associated with germline mutation and 60% were sporadic (Dahia, 2014; Pillai et al., 2016). Meanwhile, the mechanism of tumorigenesis, particularly that of tumour growth, in pheochromocytoma has been controversial. One of the mechanisms of tumour growth and progression is angiogenesis. Pheochromocytoma is a highly vascular tumour. The



vascular endothelial growth factor (VEGF)-A, the main component of the VEGF family, promotes the growth of vascular endothelial cells derived from blood vessels (Ferrara et al., 2003). VEGF-A plays a key regulatory role in angiogenesis and tumour progression, which initiates two major cascades of tumorigenesis, the RAS-BRAF-MEK pathway and PI3K-AKT-mTOR pathway, in various tumours as well as in pheochromocytoma (Carmeliet, 2005; McCubrey et al., 2007; Dahia, 2014; Molinaro, et al., 2017). In addition, the roles of VEGF-B and VEGF-C, which are components of the VEGF family, have not been fully revealed in pheochromocytoma. In the literature, some studies showed the roles of VEGF-B and VEGF-C in the pathogenesis in several cancers (Salven et al., 1998; Skobe et al., 2001; Weekes et al., 2009; Tammela and Alitalo et al., 2010; Salajegheh et al. 2013; Yang et al., 2015; Pan et al., 2018). Furthermore, some reports indicated that VEGF-B/VEGF-C could facilitate the action of VEGF-A (Cleaver and Melton, 2003; Ferrara et al., 2003).

In the previous study, mouse double minute 2 (MDM2) was reported to regulate VEGF-A expression in several tumours (Zhou et al., 2011; Xiong et al., 2014; Bradbury et al., 2015). Besides, Lam and co-workers showed mutated p53 protein or expression of MDM2 were poor predictive markers for pheochromocytoma (Lam et al., 2001). Thus, in the present study, we investigated the expressions of different VEGFs and correlated these with the expressions of p53, MDM2 as well as the clinicopathological features of patients with non-hereditary, non-metastatic pheochromocytomas.

Materials and methods

Materials

Ethical approval for this study was obtained by Griffith University human research ethics committee (GU ref. nos.: MED/19/08/HREC approved 27 July 2009). The patients (10 men; 10 women) selected for this study had non-hereditary, non-metastatic pheochromocytoma. They were operated between 1973 and 2015 by surgeons in Hong Kong and Australia (CYL and VL). The non-hereditary base of these pheochromocytomas were based on the genetic profiles as detailed in our previous studies as well as from clinical data (Pillai et al., 2016). In addition, all the patients had more than 5 year of clinical follow-up to confirm that the tumours were non-metastasizing. All these pheochromocytomas were prospectively collected and with clinical data and tissue blocks available as well as with pathological diagnoses confirmed by the author (AKL). After reviewing the histological sections of the tumours, a block was chosen from each of the pheochromocytomas. The selection of block from each patient was based on having adequate portion of tumour tissue (>70% of area occupied by non-necrotic tumour). The characteristics of the patients with

pheochromocytoma used in the study are shown in Table 1. In addition, non-neoplastic adrenal tissues were collected as controls. These non-neoplastic adrenal tissues were from patients with adrenal resected together with renal cell carcinomas during the operation as a part of the procedure. From each of these non-neoplastic adrenal glands, the adrenal medulla region was micro-dissected out for RNA and DNA extractions.

mRNA extraction and reverse transcription

Total RNA was extracted from formalin-fixed, paraffin-embedded tissue samples using Qiagen miRNA easy FFPE kits (Qiagen, Hilden, Germany), which were specially designed for purifying total RNA from formalin-fixed, paraffin-embedded tissue sections. Reverse transcription reactions were performed using 1 µg total RNA in a final reaction volume of 20 µl. RNA was converted to cDNA using miScript Reverse Transcription Kit (Qiagen) according to the manufacturer's instructions. The quality of cDNA was checked by measuring optical density. Each cDNA sample was diluted to 30 ng/µl and was stored at -20°C until the polymerase chain reaction (PCR) analysis.

Quantitative real-time PCR

VEGF-A/VEGF-B/VEGF-C mRNA expressions of each tested sample were examined using quantitative real-time PCR by QuantStudio 6 Flex Real-Time PCR System (ThermoFisher Scientific, Waltham, MA) according to the protocol described previously (Lam et al., 2011; Kasem et al., 2014). Primers for VEGF-A were 5'-TCTTCAAGCCATCCTGTGTG-3' for forward and 5'-TCTGCATGGTGATGTTGGAC-3' for reverse. The VEGF-B primers were 5'-ACCCCAACCCTGATAAAAG-3' for forward and 5'-TCCTCATTTCCTCCATCTGC-3' for reverse. The VEGF-C primers were 5'-GGAAAGAAGTTCCACCACCA-3' for forward and 5'-TGTTAGCATGGACCCACAAG-3' for reverse. The GAPDH (glyceraldehyde 3-phosphate dehydro-

Table 1. Clinical characteristics, VEGF-A/VEGF-B/VEGF-C mRNA expressions, and p53/MDM2 protein expression of the patients with pheochromocytoma.

Total number of patients = 20	
Mean age ± standard deviation (years)	41±16
Gender (Female/Male)	10/10
Tumour laterality (Right/Left)	16/4
Mean tumour size ± standard deviation (mm)	65±25
Morbidity of hypertension	20 (100 %)
Morbidity of diabetes mellitus	3 (15%)
Patients with expression of VEGF-A	11 (55%)
Patients with expression of VEGF-B	9 (45%)
Patients with expression of VEGF-C	9 (45%)
Patients with positive expression of p53	0 (0%)
Patients with positive expression of MDM2	9 (45%)

VEGF-A/VEGF-B/VEGF-C in pheochromocytoma

genase) primers were 5'-TGCACCACCAACTGC TTAGC-3' for forward and 5'-GCATGCACTGTGGTC ATGAG-3' for reverse. The fold changes in the target genes were calculated for each sample group using the $2^{-\Delta\Delta C_t}$ method with *GAPDH* and control samples of normal adrenal medulla tissue. The fold changes more than 2 were considered over-expression.

Investigation of p53 and MDM2 protein expression

All tissues from patients with pheochromocytoma were examined for expressions of p53 protein and MDM2 protein using immunohistochemistry as previously described (Lam et al., 2001). The immunostaining of p53 and MDM2 was analysed by a pathologist (AKL) under a standard light microscope. Grading of "0" and "1" were used for this assessment, where "0" represented negative protein staining and "1" represented protein staining.

Data analysis

Statistical analyses were performed using STATA[®] SE version 13.1 (Stata Corporation, College Station, TX, USA). Comparisons between variable groups were analysed using the χ^2 test. Significance of differences was taken as $p < 0.05$.

Results

Expression of VEGF-A/VEGF-B/VEGF-C mRNA and MDM2 protein in patients with sporadic, non-metastatic pheochromocytomas (Table 1)

High expressions of *VEGF-A*, *VEGF-B*, and *VEGF-C* mRNA were detected in 55% (11/20), 45% (9/20), and 45% (9/20) of the tumours, respectively. MDM2 protein was positive in 45% (9/20) (Fig. 1) whereas p53 protein was negative in all pheochromocytomas (Fig. 2).




Fig. 1. Positive nuclear expression of MDM2 protein (3,3'-diaminobenzidine/haematoxylin). Scale bar: 50 μ m.

Correlation between VEGF-A/VEGF-B/VEGF-C mRNA expressions and clinicopathological factors (Table 2)

VEGF-A expression was significantly correlated with larger tumour size ($p=0.025$). Overall, 73% of tumours of diameter ≥ 50 mm had high *VEGF-A* expression. Meanwhile, high expression of *VEGF-B* or *VEGF-C* did not correlate with tumour size ($p=0.178$). *VEGF-A/VEGF-B/VEGF-C* expressions did not correlate with age, gender of the patients or tumour laterality ($p > 0.1$). Besides, *VEGF-A* expression correlated with MDM2 protein expression with near statistical significance ($p=0.064$). In summary, 64% of tumours with high *VEGF-A* expression were positive for MDM2, while 22% of tumours with low *VEGF-A* expression were positive for MDM2 expression. High expressions of *VEGF-B* or *VEGF-C* was not correlated with MDM2 expression ($p > 0.3$).

Correlation upon tumour growth between VEGF-A mRNA expression and VEGF-B/VEGF-C mRNA expression (Table 3)

High expression of *VEGF-B* with high expression of *VEGF-A* is associated with larger tumour ($p=0.042$). In summary, 86% of pheochromocytomas with high expression of both *VEGF-B* and *VEGF-A* were of diameter ≥ 50 mm (mean diameter=76 mm). On the other hand, 50% of pheochromocytomas with high expression of *VEGF-A* and low expression of *VEGF-B* had diameter ≥ 50 mm (mean diameter=60mm). In addition, only 22% of pheochromocytomas with low




Fig. 2. **A.** Positive nuclear expression of p53 protein in a familial paraganglioma (control). **B.** negative nuclear expression of p53 in non-familial, no metastasising pheochromocytoma (3,3'-diaminobenzidine/haematoxylin). Scale bar: 100 μ m.

VEGF-A/VEGF-B/VEGF-C in pheochromocytoma

Table 2. Clinicopathological variables and VEGF-A/VEGF-B/VEGF-C expressions in patients with non-hereditary, non-metastatic pheochromocytoma.

		VEGF-A			VEGF-B			VEGF-C		
		Patients with high expression	Patients with low expression	P	Patients with high expression	Patients with high expression	P	Patients with high expression	Patients with high expression	P
Tumour size (mm)	Less than 50	3 (15%)	7 (35%)	0.025*	3 (15%)	7 (35%)	0.178	3 (15%)	7 (35%)	0.178
	Over (or=50)	8 (40%)	2 (10%)		6 (30%)	4 (20%)		6 (30%)	4 (20%)	
Age (years)	Less than 40	5 (25%)	6 (30%)	0.343	5 (25%)	6 (30%)	0.582	4 (20%)	7 (35%)	0.391
	Over (or=40)	6 (30%)	3 (15%)		4 (20%)	5 (25%)		5 (25%)	4 (20%)	
Gender	Female	5 (25%)	5 (25%)	0.653	6 (30%)	4 (20%)	0.068	5 (25%)	5 (25%)	0.653
	Male	6 (30%)	4 (20%)		3 (15%)	7 (35%)		4 (20%)	6 (30%)	
Laterality	Right	8 (40%)	8 (40%)	0.369	6 (30%)	10 (50%)	0.110	7 (35%)	9 (45%)	0.822
	Left	3 (15%)	1 (5%)		3 (15%)	1 (5%)		2 (10%)	2 (10%)	
MDM2 expression	Positive	7 (35%)	2 (10%)	0.064	5 (25%)	4 (20%)	0.391	5 (25%)	4 (20%)	0.391
	Negative	4 (20%)	7 (35%)		4 (20%)	7 (35%)		4 (20%)	7 (35%)	

*p<0.05 was considered significant.

Table 3. Detailed evaluation of the correlation of tumour growth between VEGF-A expression and VEGF-B/VEGF-C expressions in patients with non-hereditary, non-metastatic pheochromocytomas.

	VEGF-A: patients with high expression		VEGF-A: patients with low expression	p
	VEGF-B: patients with high expression	VEGF-B: patients with low expression		
Tumour size (mm)				
Less than 50	1 (5%)	2 (10%)	7 (35%)	0.042*
Over (or=50)	6 (30%)	2 (10%)	2 (10%)	
Size (mean ± SD)	76±18	60±21	58±30	
	VEGF-A: patients with high expression		VEGF-A: patients with low expression	p
	VEGF-C: patients with high expression	VEGF-C: patients with low expression		
Tumour size (mm)				
Less than 50	2 (10%)	1 (5%)	7 (35%)	0.078
Over (or=50)	6 (30%)	2 (10%)	2 (10%)	
Size (mean ± SD)	74±19	61±23	58±30	

SD: standard deviation; *p<0.05 was considered significant.

Table 4. Detailed evaluation of the correlation of MDM2 protein expression between VEGF-A expression and VEGF-B/VEGF-C expressions in patients with non-hereditary, non-metastatic pheochromocytomas.

	VEGF-A: patients with high expression		VEGF-A: patients with low expression	p
	VEGF-B: patients with high expression	VEGF-B: patients with low expression		
MDM2 protein				
Positive	5 (25%)	2 (10%)	2 (10%)	0.142
Negative	2 (10%)	2 (10%)	7 (35%)	
	VEGF-A: patients with high expression		VEGF-A: patients with low expression	p
	VEGF-C: patients with high expression	VEGF-C: patients with low expression		
MDM2 protein				
Positive	5 (25%)	2 (10%)	2 (10%)	0.179
Negative	3 (15%)	1 (5%)	7 (35%)	

*p<0.05 was considered significant.

VEGF-A/VEGF-B/VEGF-C in pheochromocytoma

expression of both *VEGF-A* and *VEGF-B* had diameter ≥ 50 mm (mean diameter = 58 mm). Moreover, 75% of pheochromocytomas with high expressions of *VEGF-C* and *VEGF-A* had diameter ≥ 50 mm (mean diameter = 74 mm), whereas 67% of pheochromocytomas with high expression of *VEGF-A* and low expression of *VEGF-C* had tumour with diameter ≥ 50 mm (mean diameter = 61 mm). Furthermore, pheochromocytomas having high expressions of *VEGF-C* and *VEGF-A* were associated with larger tumour size, but not significantly ($p=0.078$).

Correlations of MDM2 protein expression between VEGF-A mRNA expression and VEGF-B/VEGF-C mRNA expression (Table 4)

Overall, 71% of pheochromocytomas with high expressions of *VEGF-B* and *VEGF-A* were positive for MDM2. In addition, 50% of pheochromocytomas with high expression of *VEGF-A* and low expression of *VEGF-B* were positive for MDM2, whereas 22% of pheochromocytomas with low expression of *VEGF-A* expression were positive for MDM2. However, high expressions of *VEGF-B* and *VEGF-A* did not significantly correlate with MDM2 expression ($p=0.142$). Furthermore, 63% of pheochromocytomas with high expression of *VEGF-C* and *VEGF-A* were positive for MDM2 whereas 67% of pheochromocytomas with high *VEGF-A* expression and low *VEGF-C* expression were positive for MDM2. High expression of *VEGF-C* and *VEGF-A* did not significantly correlate with MDM2 expression ($p=0.179$).

Discussion

This study is the first pilot study on the roles of VEGF-B/VEGF-C in addition to VEGF-A in non-hereditary, non-metastatic pheochromocytoma. Besides, this study is also the first to analyse the correlation between VEGF-A/VEGF-B/VEGF-C and MDM2, which plays a crucial role in tumorigenesis of pheochromocytomas.

VEGF-A is the key mediator of angiogenesis in cancers, which is essential for cancer development and growth (Ferrara and Davis-Smyth, 1997; Ferrara et al., 2003; Carmeliet, 2005). It could promote the growth of vascular endothelial cells derived from blood vessels and lymphatics (Ferrara and Davis-Smyth, 1997; Ferrara et al., 2003). Tumour vasculature, which is affected by VEGF-A, was reported to be structurally and functionally abnormal due to pathological angiogenesis associated with tumour growth (Ferrara and Davis-Smyth, 1997; Ferrara et al., 2003). Besides, VEGF-A expression correlated with lymph node metastases in malignancies, such as in papillary thyroid carcinoma (Salajegheh et al., 2013). VEGF-A induces angiogenesis and proliferation mainly through vascular endothelial growth factor receptor (VEGFR)-2. In addition, VEGF-A affect angiogenesis through VEGFR-1 by promoting induction of matrix metalloproteinase (MMP)-9,

urokinase-type plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) (Bergers et al., 2000; Ferrara et al., 2003; Carmeliet and Jain, 2011).

In pheochromocytoma, the function of VEGF-A has been investigated (Feng et al., 2011; Ferreira et al., 2014). Feng and co-workers showed the rate of positive VEGF-A protein expression in patients with metastatic pheochromocytoma was higher than that in patients with non-metastatic pheochromocytoma (Feng et al., 2011). Ferreira and co-workers showed positive VEGF-A protein expression on immunostaining in patients with metastatic pheochromocytoma was more common than that in patients with non-metastatic pheochromocytoma (Ferreira et al., 2014). In addition, there was no significant difference of VEGF-A expression between patients with sporadic, non-metastatic pheochromocytoma and those with multiple endocrine neoplasia type 2 (MEN2) associated pheochromocytoma. In the study, VEGF-A protein expression did not significantly associate with tumour size in all patients with pheochromocytoma, which included metastatic or MEN2 associated pheochromocytomas (Ferreira et al., 2014). In the present study, *VEGF-A* expression significantly correlated with tumour size ($p=0.025$). This discrepancy might be due to the different subjects being studied. In this study, we exam a more unique group of patients who have non-hereditary, non-metastatic pheochromocytomas.

Recent studies revealed that VEGF-B or VEGF-C had roles for tumorigenesis in some cancers in addition to VEGF-A. VEGF-B was initially revealed to stimulate endothelial cell activity and promotes angiogenesis (Olofsson et al., 1996). VEGF-B expression was detected in several malignancies and associated with tumour angiogenesis (Salven, et al., 1998). VEGF-B promotes induction of MMP-9 through VEGFR1. Yang and co-workers reported that expression of VEGF-B impaired primary tumour growth of melanoma and fibrosarcoma as well as induced metastases in vivo and in vitro study. Besides, expression of VEGF-B in squamous cell carcinoma of lung and melanoma correlated with poor patients' survival (Yang et al., 2015). Meanwhile, Albrecht and co-workers reported VEGF-B inhibited angiogenesis in pancreatic endocrine tumour (Albrecht et al., 2010). Thus, VEGF-B function in tumour progression remains controversial. The expression and function of VEGF-B have not been investigated in pheochromocytoma.

VEGF-C promotes angiogenesis of various tumours (Salven et al., 1998; Kodama et al., 2008). In addition, VEGF-C promotes lymphangiogenesis and increases lymph node metastases of several malignancies (Skobe et al., 2001; Tammela and Alitalo et al., 2010; Salajegheh et al., 2013; Pan et al., 2018). The protein induces angiogenesis through VEGFR2 and lymphangiogenesis through VEGFR3 (Ferrara et al., 2003; Matsumoto et al., 2013; Kasem et al., 2014). In pheochromocytoma, there is correlation noted between *VEGF-C* expression and *VEGF-A* expression (Isobe et al., 2006), but no studies have demonstrated the function

of VEGF-C in the tumour.

In the present study, *VEGF-B* expression is first being analysed in pheochromocytoma. Besides, we investigated the association between *VEGF-B/VEGF-C* expression and clinicopathological factors. The findings showed that *VEGF-B/VEGF-C* expression did not correlate all these factors. On the other hand, we demonstrated the facilitative function of VEGF-B/VEGF-C with VEGF-A in tumour growth. VEGF-B could assist VEGF-A function of tumour growth by two possible mechanism; 1) more VEGF-A binds to VEGFR-2 compared to VEGFR-1 due to competitive binding of VEGF-B to VEGFR-1; 2) induction of MMP9, uPA, and tPA by VEGF-B promotes tumour angiogenesis in addition to the function of angiogenesis by VEGF-A. Furthermore, VEGF-C might assist VEGF-A function of tumour growth through VEGFR-2 together and promote angiogenesis. The results in this study showing high expression of *VEGF-B* and *VEGF-A* are associated with significant increase of tumour size. On the contrary, high expression of *VEGF-C* and *VEGF-A* is related to increase of tumour size though the effect was not of significant. The results indicate that *VEGF-B* has more facilitative roles in the function of *VEGF-A* in promoting tumour growth than *VEGF-C* in non-hereditary, non-metastatic pheochromocytoma.

In this study, MDM2 expression was detected in 45% of patients with non-hereditary, non-metastatic pheochromocytoma. p53 is a well-known tumour suppressor and mutant forms of p53 are positive for immunostaining because of having longer half-lives. Considering p53 mutations existing in metastatic pheochromocytoma more than non-metastatic pheochromocytoma (Yoshimoto, et al., 1998), it could explain that all patients were negative for p53 in our study cohorts. On the other hand, MDM2 expression was detected in approximately half of the patients. MDM2 is well-known as a suppressor of p53, and expression of MDM2 leads to promote tumour progression in the p53-dependent pathway. Furthermore, MDM2 regulates cellular proliferation, cell migration and invasion, apoptosis, and angiogenesis in p53-independent pathway in cancers (Zhang et al., 2003; Huang et al., 2016). Zhou and co-workers showed MDM2 could bind to the VEGF-A mRNA directly and regulate *VEGF-A* stability in human neuroblastoma cells (Zhou et al., 2011). In addition, Xiong and colleagues revealed MDM2 regulated angiogenesis and tumour growth via VEGF-A in breast carcinoma, and the role of MDM2 in VEGF-A could be through p53-independent pathway in vivo and in vitro (Xiong et al., 2014). This finding consistent with our results on pheochromocytoma in which MDM2 positivity could associate with *VEGF-A* expression without p53 mutation.

In pheochromocytoma, detection of high expression of VEGF-A was reported previously but its regulation and mechanism has been unknown. The results in this study indicated VEGF-A expression could be regulated by MDM2 expression. Besides, this study revealed not

only *VEGF-B/VEGF-C* but also co-expression of *VEGF-B/VEGF-C* and *VEGF-A* did not associate with MDM2 expression. Regarding the association between expressions of MDM2 and VEGF-B/VEGF-C, there were no previous reports in pheochromocytoma or other human tumours. Our results indicated that in pheochromocytoma, over-expression of *VEGF-B/VEGF-C* might not be affected by MDM2. Thus, the effect on tumour growth by co-over-expression of *VEGF-B/VEGF-C* and *VEGF-A* in pheochromocytoma might not depend on MDM2.

This study had several limitations. First, the study cohort of this study was small because pheochromocytoma is a rare tumour, and we investigated only non-hereditary, non-metastatic pheochromocytomas. Second, we did not perform the investigations about somatic mutations. Thirdly, *VEGF* mRNA expression, instead of protein expression, was used to correlate with expression of p53 protein and MDM2 protein. On the other hand, in our previous studies using tissue blocks, we noted that correlations of *VEGF* mRNA expression could be better studied (with respect to technical aspects) by mRNA expression and could show the interactions with protein expression such as p53 (Salajegheh et al., 2013; Maroof et al., 2019). It also worth noting that expression of VEGF mRNA and protein expression correlates with each other (Salajegheh et al., 2013). Thus, future studies are required to confirm the findings of this study.

To conclude, this study revealed a role of VEGF-A as well as VEGF-B/VEGF-C in the pathogenesis of non-hereditary, non-metastatic pheochromocytoma. Furthermore, the possible correlation between expressions of MDM2 and VEGF-A is demonstrated in non-hereditary, non-metastatic pheochromocytomas. These results might lead to new knowledge about tumour growth of pheochromocytoma. The consideration of interactions of VEGF-A/VEGF-B/VEGF-C in pheochromocytoma should be recommended. Future studies are required to confirm our results and investigate the mechanisms of VEGFs in pheochromocytomas.

Acknowledgements. The authors would like to thank the members in Molecular Pathology group in Griffith University and Pathology Queensland in the help of the project.

Conflict of interest. None.

Funding. None.

Availability of data and materials. On request.

Authors' contribution. Ichiro Abe: running of experiments; drafting of manuscript. Farhadul Islam: supervision on the experimental works. Chung Yau Lo: clinical data and specimen collection. Victor Liew: clinical data and specimen collection. Suja Pillai: contribution to experimental works. Alfred K. Lam: overall supervision; revision of manuscript.

Ethical approval and consent to participate. Ethical approval for this study was obtained by Griffith University human research ethics committee (GU ref. nos.: MED/19/08/HREC).

VEGF-A/VEGF-B/VEGF-C in pheochromocytoma

References

- Abe I., Fujii H., Ohishi H., Sugimoto K., Minezaki M., Nakagawa M., Takahara S., Kudo T., Abe M., Ohe K., Yanase T. and Kobayashi K. (2019). Differences in the actions of adrenaline and noradrenaline with regard to glucose intolerance in patients with pheochromocytoma. *Endocr. J.* 66, 187-192.
- Abe I., Nomura M., Watanabe M., Shimada S., Kohno M., Matsuda Y., Adachi M., Kawate H., Ohnaka K. and Takayanagi R. (2012). Pheochromocytoma crisis caused by *Campylobacter fetus*. *Int. J. Urol.* 19, 465-467.
- Albrecht I., Kopfstein L., Strittmatter K., Schomber T., Falkevall A., Hagberg C.E., Lorentz P., Jeltsch M., Alitalo K., Eriksson U., Christofori G. and Pietras K. (2010). Suppressing effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. *PLoS One* 5, e14109.
- Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z. and Hanahan D. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. *Nat. Cell. Biol.* 2, 737-744.
- Bradbury R., Jiang W.G. and Cui Y.X. (2015). The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers. *Biomark Med.* 9, 1353-1370.
- Bravo E. (1994). Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. *Endocr. Rev.* 15, 356-368.
- Carmeliet P. (2005). VEGF as a key mediator of angiogenesis in cancer. *Oncology* 69, 4-10.
- Carmeliet P. and Jain R.K. (2011). Molecular mechanisms and clinical applications of angiogenesis. *Nature* 473, 298-307.
- Cleaver O. and Melton D.A. (2003). Endothelial signaling during development. *Nat. Med.* 9, 661-668.
- Dahia P.L. (2014). Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. *Nat. Rev. Cancer.* 14, 108-119.
- Eisenhofer G., Lenders J.W., Goldstein D.S., Mannelli M., Csako G., Walther M.M., Brouwers F.M. and Pacak K. (2005). Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. *Clin. Chem.* 51, 735-744.
- Feng F., Zhu Y., Wang X., Wu Y., Zhou W., Jin X., Zhang R., Sun F., Kasoma Z. and Shen Z. (2011). Predictive factors for malignant pheochromocytoma: analysis of 136 patients. *J. Urol.* 185, 1583-1590.
- Ferrara N. and Davis-Smyth T. (1997). The biology of vascular endothelial growth factor. *Endocr. Rev.* 18, 4-25.
- Ferrara N., Gerber H.P. and LeCouter J. (2003). The biology of VEGF and its receptors. *Nat. Med.* 9, 669-676.
- Ferreira C.V., Siqueira D.R., Romitti M., Ceolin L., Brasil B.A., Meurer L., Capp C. and Maia A.L. (2014). Role of VEGF-A and its receptors in sporadic and MEN2-associated pheochromocytoma. *Int. J. Mol. Sci.* 15, 5323-5336.
- Huang Q., Li L., Li L., Chen H., Dang Y., Zhang J., Shao N., Chang H., Zhou Z., Liu C., He B., Wei H. and Xiao J. (2016). MDM2 knockdown mediated by a triazine-modified dendrimer in the treatment of non-small cell lung cancer. *Oncotarget* 7, 44013-44022.
- Isobe K., Nissato S., Tatsuno I., Yashiro T., Takekoshi K. and Kawakami Y. (2006). Expression of mRNAs for succinate dehydrogenase subunits and related genes in pheochromocytoma. *Ann. NY Acad. Sci.* 1073, 253-262.
- Kasem K., Sullivan E., Gopalan V., Salajegheh A., Smith R.A. and Lam A.K. (2014). JK1 (FAM134B) represses cell migration in colon cancer: a functional study of a novel gene. *Exp. Mol. Pathol.* 97, 99-104.
- Kodama M., Kitadai Y., Tanaka M., Kuwai T., Tanaka S., Oue N., Yasui W. and Chayama K. (2008). Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. *Clin. Cancer Res.* 14, 7205-7214.
- Lam A.K., Gopalan V., Nassiri M.R., Kasim K., Dissanayake J., Tang J.C. and Smith R.A. (2011). Altered JS-2 expression in colorectal cancers and its clinical pathological relevance. *Mol. Oncol.* 5, 475-481.
- Lam A.K. (2015). Updated on paragangliomas and pheochromocytomas. *Turk. Patoloji. Derg.* 31, 105-112.
- Lam A.K. (2017). Update on adrenal tumors in 2017 World Health Organization (WHO) of endocrine tumors. *Endocr. Pathol.* 28, 213-227.
- Lam K.Y., Lo C.Y., Wat N.M.S., Luk J.M. and Lam K.S.L. (2001). The clinicopathological features and importance of p53, Rb and mdm2 expression in pheochromocytomas and paragangliomas. *J. Clin. Pathol.* 54, 443-448.
- Lloyd R.V., Osamura R.Y., Kloppel G. and Rosai J. (2017). WHO classification of tumors: pathology and genetics of tumors of endocrine organs. 4th ed. IARC. Lyon.
- Maroof H., Irani S., Arianna A., Vider J., Gopalan V. and Lam A.K. (2019). Interactions of vascular endothelial growth factor and p53 with miR-195 in thyroid carcinoma: possible therapeutic targets in aggressive thyroid cancers. *Curr. Cancer Drug Targets* 19, 561-570.
- Matsumoto M., Roufail S., Inder R., Caesar C., Karnezis T., Shayan R., Farnsworth R.H., Sato T., Achen M.G., Mann G.B. and Stacker S.A. (2013). Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. *Clin. Exp. Metastasis* 30, 819-832.
- McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M. and Franklin R.A. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochim. Biophys. Acta* 1773, 1263-1284.
- Molinaro E., Romei C., Biagini A., Sabini E., Agate L., Mazzeo S., Materazzi G., Sellari-Franceschini S., Ribecchini A., Torregrossa L., Basolo F., Vittori P. and Elisei R. (2017). Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. *Nat. Rev. Endocrinol.* 13, 644-660.
- Newell K., Prinz R.A., Braithwaite S. and Brooks M. (1988). Pheochromocytoma crisis. *Am. J. Hypertens.* 1, 189S-191S.
- Olofsson B., Pajusola K., Kaipainen A., von Euler G., Joukov V., Saksela O., Orpana A., Pettersson R.F., Alitalo K. and Eriksson U. (1996). Endothelial growth factor B, a novel growth factor for endothelial cells. *Proc. Natl. Acad. Sci. USA* 93, 2576-2581.
- Pan Z., Lu X., Zhao J., Gao Q. and Wang J. (2018). VEGF-C is positively associated with lymphangiogenesis and lymphatic metastasis in rectal cancer. *Int. J. Clin. Exp. Pathol.* 11, 1777-1783.
- Papathomas T.G., Suurd D.P.D., Pacak K., Tischler A.S., Vriens M.R., Lam A.K. and de Krijger RR. (2021). What have we learned from molecular biology of paragangliomas and pheochromocytomas?. *Endocr. Pathol.* 32, 134-153.
- Pillai S., Gopalan V., Smith R.A. and Lam A.K. (2016). Updates on the genetics and the clinical impacts on pheochromocytoma and paraganglioma in the new era. *Crit. Rev. Oncol. Hematol.* 100, 190-

- 208.
- Riester A., Weismann D., Quinkler M., Lichtenauer U.D., Sommerey S., Halbritter R., Penning R., Spitzweg C., Schopohl J., Beuschlein F. and Reincke M. (2015). Life-threatening events in patients with pheochromocytoma. *Eur. J. Endocrinol.* 173, 757-764.
- Salajegheh A., Pakneshan S., Rahman A., Dolan-Evans E., Zhang S., Kwong E., Gopalan V., Lo C.Y., Smith R.A. and Lam A.K. (2013). Co-regulatory potential of vascular endothelial growth factor–A and vascular endothelial growth factor–C in thyroid carcinoma. *Hum. Pathol.* 44, 2204-2212.
- Salven P., Lymboussaki A., Heikkilä P., Jääskela-Saari H., Enholm B., Aase K., von Euler G., Eriksson U., Alitalo K. and Joensuu H. (1998). Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. *Am. J. Pathol.* 153, 103-108.
- Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K. and Detmar M. (2001). Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nat. Med.* 7, 192-198.
- Tammela T. and Alitalo K. (2010). Lymphangiogenesis: Molecular mechanisms and future promise. *Cell* 140, 460-476.
- Tevosian S.G. and Ghayee H.K. (2019). Pheochromocytomas and paragangliomas. *Endocrinol. Metab. Clin. North. Am.* 48, 727-750.
- Weekes J., Lam A.K., Sebesan S. and Ho Y.H. (2009). Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. *World J. Gastroenterol.* 15, 3597-3602.
- Xiong J., Yang Q., Li J. and Zhou S. (2014). Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer. *Angiogenesis* 17, 37-50.
- Yang X., Zhang Y., Hosaka K., Andersson P., Wang J., Tholander F., Cao Z., Morikawa H., Tegnér J., Yang Y., Iwamoto H., Lim S. and Cao Y. (2015). VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients. *Proc. Natl. Acad. Sci. USA* 112, E2900-2909.
- Yoshimoto T., Naruse M., Zeng Z., Nishikawa T., Kasajima T., Toma H., Yamamori S., Matsumoto H., Tanabe A., Naruse K. and Demura H. (1998). The relatively high frequency of p53 gene mutations in multiple and malignant pheochromocytomas. *J. Endocrinol.* 159, 247-255.
- Zhang Z., Li M., Wang H., Agrawal S. and Zhang R. (2003). Antisense therapy targeting mdm2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. *Proc. Natl. Acad. Sci. USA* 100, 11636-11641.
- Zhou S., Gu L., He J., Zhang H. and Zhou M. (2011). MDM2 regulates vascular endothelial growth factor mRNA stabilisation in hypoxia. *Mol. Cell. Biol.* 31, 4928-4937.

Accepted march 18, 2021